Summary: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.

Top Publications

  1. Moorthi R, Moe S. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011;58:1022-36 pubmed publisher
  2. Kuro O M. Calciprotein particle (CPP): a true culprit of phosphorus woes?. Nefrologia. 2014;34:1-4 pubmed publisher
  3. Manfro R, Pedroso J, Pegas K, Gonçalves L. Acute phosphate nephropathy in a kidney transplant recipient with delayed graft function. Transplantation. 2009;87:618-9 pubmed publisher
  4. Coyne D, Ficociello L, Parameswaran V, Anderson L, Vemula S, Ofsthun N, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
. Clin Nephrol. 2017;88:59-67 pubmed publisher
    b>Hyperphosphatemia has been associated with an increased risk of mortality in patients with end-stage renal disease...
  5. Ketteler M, Wolf M, Hahn K, Ritz E. Phosphate: a novel cardiovascular risk factor. Eur Heart J. 2013;34:1099-101 pubmed publisher
  6. Szoke D, Dolci A, Genderini A, Panteghini M. Fatal electrolyte abnormalities following enema administration. Clin Chem. 2012;58:1515-8 pubmed publisher
  7. Rafaelsen S, Johansson S, Ræder H, Bjerknes R. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature. BMC Genet. 2014;15:98 pubmed publisher
    ..HHS and HFTC are two distinct phenotypes in a spectrum of GALNT3 mutation related calcification disorders, where the additional factors determining the phenotypic expression, are yet to be clarified. ..
  8. Demellawy D, Chang N, de Nanassy J, Nasr A. GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis. Scand J Rheumatol. 2015;44:170-2 pubmed publisher
  9. Sun Y, Yang W, Li S, Han Y, Liu J. Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent Hemodialysis Patients in the Xinjiang Uyghur Autonomous Region in China. Biomed Res Int. 2017;2017:2516934 pubmed publisher
    ..Serum P levels were higher than in DOPPS4 and lower than those in the Chinese DOPPS. Hyperphosphatemia rates were higher than DOPPS4 and lower than Chinese DOPPS...

More Information


  1. St Peter W, Wazny L, Weinhandl E, Cardone K, Hudson J. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?. Drugs. 2017;77:1155-1186 pubmed publisher
    As kidney disease progresses, phosphorus retention also increases, and phosphate binders are used to treat hyperphosphatemia. Clinicians prescribe phosphate binders thinking that reducing total body burden of phosphorus may decrease ..
  2. Merhi B, SHIREMAN T, Carpenter M, Kusek J, Jacques P, Pfeffer M, et al. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. Am J Kidney Dis. 2017;70:377-385 pubmed publisher
    Mild hyperphosphatemia is a putative risk factor for cardiovascular disease [CVD], loss of kidney function, and mortality...
  3. Chao C, Liu Y, Su S, Yeh H, Chen H, Lee P, et al. Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification. Arterioscler Thromb Vasc Biol. 2017;37:1402-1414 pubmed publisher
    ..rat and human aortic vascular smooth muscle cells were treated with high levels of phosphate to mimic uremic hyperphosphatemia. Using an Affymetrix microRNA array, we found that miR-125b and miR-382 expression levels declined ..
  4. Ignaszewski M, Kohlitz P. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. Am J Emerg Med. 2017;35:1384.e1-1384.e2 pubmed publisher
    ..occurred in a 69-year-old male with metastatic prostate adenocarcinoma with hyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia, elevated liver enzymes, AKI and hemodynamic instability...
  5. Broman M, Wilsson A, Hansson F, Klarin B. Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort. Anesth Analg. 2017;124:1897-1905 pubmed publisher
    ..during 2006-2014 were retrospectively divided into a control group and 3 study groups: hypophosphatemia, hyperphosphatemia, and a mixed group showing both hypo/hyperphosphatemia...
  6. Strauss P, Hamlin S, Dang J. Tumor Lysis Syndrome: A Unique Solute Disturbance. Nurs Clin North Am. 2017;52:309-320 pubmed publisher
    ..Advanced practice nurses may be in the position of triaging and initiating treatment of patients with TLS, and need a thorough understanding of the syndrome and its treatment. ..
  7. Shang D, Xie Q, Shang B, Zhang M, You L, Hao C, et al. Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. Biomed Res Int. 2017;2017:2520510 pubmed publisher
    ..Multivariate analysis revealed that hyperphosphatemia and hs-CRP were the independent risk factors for CAC initiation after adjustments. Conclusions...
  8. Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363:2287-300 pubmed publisher
    ..71; 95% CI, 1.08 to 2.73). Frequent hemodialysis was associated with improved control of hypertension and hyperphosphatemia. There were no significant effects of frequent hemodialysis on cognitive performance, self-reported ..
  9. Liou H. What can a keto acid/amino acid-supplemented protein-restricted diet do for the "butterfly effect" in chronic kidney disease patients?. J Ren Nutr. 2009;19:S15-8 pubmed publisher